| 王 文,王红兵.TKIs治疗EML4-ALK阳性非小细胞肺癌脑转移的研究进展[J].肿瘤学杂志,2018,24(1):11-15. |
| TKIs治疗EML4-ALK阳性非小细胞肺癌脑转移的研究进展 |
| Research Progress on Targeted Therapy of EML4-ALK Positive Non-small Cell Lung Cancer with Brain Metastasis |
| 投稿时间：2017-02-14 |
| DOI：10.11735/j.issn.1671-170X.2018.01.B003 |
|
 |
| 中文关键词: ALK抑制剂 肺癌脑转移 靶向治疗 |
| 英文关键词:ALK inhibitors NSCLC with brain metastases targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 1744 |
| 全文下载次数: 643 |
| 中文摘要: |
| 摘 要：间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）基因重排是非小细胞肺癌（NSCLC）一种新的肿瘤驱动基因，促使肺癌发生和进展。近年来针对ALK融合基因的酪氨酸激酶抑制剂崭露头角，相关药物研究在非小细胞肺癌脑转移治疗中有较大进展，成为靶向治疗的热点。全文就治疗ALK阳性NSCLC脑转移的靶向药物的临床研究作一综述。 |
| 英文摘要: |
| Abstract：Studies have demonstrated that the rearrangement of anaplastic lymphoma kinase(ALK) gene promotes the occurrence and development of lung cancer. In recent years，tyrosine kinase inhibitors targeting ALK fusion gene becomes a new focus of cancer targeted therapy，and the greater progress has been made in related drug research for non-small cell lung cancer(NSCLC) with brain metastases. In this paper，we review the latest clinical research on the targeted therapy of ALK positive NSCLC with brain metastases. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|